Could a bladder drug help POTS patients stop fainting?
NCT ID NCT06133075
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This small pilot study tested whether mirabegron, a drug typically used for overactive bladder, can raise blood pressure and reduce fainting in people with POTS who have low blood pressure that standard treatments didn't help. Twenty adults took either 25 mg or 50 mg of the drug for 8 weeks. Researchers measured blood pressure changes and tracked fainting episodes, but technical issues limited the data available for analysis.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC ORTHOSTATIC INTOLERANCE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cedars-Sinai Medical Center
Los Angeles, California, 90048, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a High-Fat diet reset energy in long COVID?
- Week-Long heart patch could Out-Sleuth standard 24-Hour monitor for palpitations
- Scientists map the many faces of POTS to unlock better care
- Can tailored exercise help tame racing heart and fatigue after COVID?
- Can immune therapy IVIG calm long COVID's autonomic storm?
- AI-Powered patch could replace ultrasound for heart checkups